Decitabine (DAC) and tazemetostat (TAZ) upregulated HLA protein in DLBCL cell lines. (A-D) Cells were treated with indicated 125 nM decitabine or 1 μM tazemetostat. DB and SUDHL-6 cells were assayed for HLA-A, -B, and -C or HLA-A-02 expression by flow cytometry. (E-H) Cells were treated as in panels A-D along with 100 ng/mL IFN-γ. Analysis of variance (ANOVA) was performed using either untreated (panels A-D) or IFN-γ alone (panels E-H) as control, followed by a post hoc Tukey’s test for individual experimental groups. Mean ± standard deviation (SD) is shown for 3 technical replicates per 2 biological replicates. ns, not significant. *P < .05; **P < .01; ***P < .001; ****P < .0001.